FY2024 EPS Estimates for Altimmune Reduced by HC Wainwright

Altimmune, Inc. (NASDAQ:ALT - Free Report) - Research analysts at HC Wainwright decreased their FY2024 earnings estimates for shares of Altimmune in a research report issued on Wednesday, November 13th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($1.28) per share for the year, down from their previous forecast of ($1.25). HC Wainwright has a "Buy" rating and a $12.00 price objective on the stock. The consensus estimate for Altimmune's current full-year earnings is ($1.36) per share. HC Wainwright also issued estimates for Altimmune's Q1 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.33) EPS, FY2025 earnings at ($1.32) EPS, FY2026 earnings at ($1.45) EPS, FY2027 earnings at ($1.45) EPS and FY2028 earnings at ($0.15) EPS.

Altimmune (NASDAQ:ALT - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.03. The firm had revenue of $0.01 million for the quarter. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. During the same quarter in the prior year, the company posted ($0.39) EPS.

A number of other research analysts have also commented on the company. Evercore ISI raised Altimmune to a "strong-buy" rating in a report on Friday, August 9th. UBS Group started coverage on shares of Altimmune in a research note on Tuesday, November 12th. They set a "buy" rating and a $26.00 target price for the company. Finally, B. Riley reaffirmed a "buy" rating and set a $20.00 price objective on shares of Altimmune in a research report on Monday, August 12th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $20.00.

Altimmune Trading Down 6.0 %

Altimmune stock traded down $0.46 during mid-day trading on Monday, hitting $7.15. 4,476,008 shares of the company's stock were exchanged, compared to its average volume of 3,874,781. Altimmune has a 1-year low of $2.41 and a 1-year high of $14.84. The stock has a 50 day moving average of $7.04 and a two-hundred day moving average of $6.91. The stock has a market cap of $508.54 million, a P/E ratio of -4.61 and a beta of 0.09.

Institutional Investors Weigh In On Altimmune

Several large investors have recently made changes to their positions in the company. Larson Financial Group LLC bought a new position in shares of Altimmune in the third quarter valued at approximately $31,000. CANADA LIFE ASSURANCE Co bought a new position in Altimmune in the 1st quarter valued at $44,000. TFO Wealth Partners LLC acquired a new position in Altimmune in the first quarter worth $51,000. Horizon Wealth Management LLC bought a new stake in shares of Altimmune during the second quarter worth $66,000. Finally, PFG Investments LLC acquired a new stake in shares of Altimmune in the second quarter valued at $67,000. Institutional investors own 78.05% of the company's stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.